Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/34080
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorFlórez Álvarez, Lizdany-
dc.contributor.authorHernández López, Juan Carlos-
dc.contributor.authorZapata Builes, Wildeman-
dc.date.accessioned2023-03-16T22:29:05Z-
dc.date.available2023-03-16T22:29:05Z-
dc.date.issued2018-
dc.identifier.citationFlórez-Álvarez L, Hernandez JC, Zapata W. NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies. Front Immunol. 2018 Oct 17;9:2290. doi: 10.3389/fimmu.2018.02290.spa
dc.identifier.urihttps://hdl.handle.net/10495/34080-
dc.description.abstractABSTRACT: NK cells play a key role in immune response against HIV infection. These cells can destroy infected cells and contribute to adequate and strong adaptive immune responses, by acting on dendritic, T, B, and even epithelial cells. Increased NK cell activity reflected by higher cytotoxic capacity, IFN-γ and chemokines (CCL3, CCL4, and CCL5) production, has been associated with resistance to HIV infection and delayed AIDS progression, demonstrating the importance of these cells in the antiviral response. Recently, a subpopulation of NK cells with adaptive characteristics has been described and associated with lower HIV viremia and control of infection. These evidences, together with some degree of protection shown in vaccine trials based on boosting NK cell activity, suggest that these cells can be a feasible option for new treatment and vaccination strategies to overcome limitations that, classical vaccination approaches, might have for this virus. This review is focus on the NK cells role during the immune response against HIV, including all the effector mechanisms associated to these cells; in addition, changes including phenotypic, functional and frequency modifications during HIV infection will be pointed, highlighting opportunities to vaccine development based in NK cells effector functions.spa
dc.format.extent13 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherFrontiers Research Foundationspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleNK Cells in HIV-1 Infection : From Basic Science to Vaccine Strategiesspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupInmunovirologíaspa
dc.identifier.doi10.3389/fimmu.2018.02290-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1664-3224-
oaire.citationtitleFrontiers in Immunologyspa
oaire.citationstartpage1spa
oaire.citationendpage13spa
oaire.citationvolume9spa
oaire.citationissue2290spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
dc.publisher.placeLausana, Suizaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTREVspa
dc.type.localArtículo de revisiónspa
dc.subject.decsKiller Cells, Natural-
dc.subject.decsCélulas Asesinas Naturales-
dc.subject.decsHIV-1-
dc.subject.decsVIH-1-
dc.subject.decsAIDS Vaccines-
dc.subject.decsVacunas contra el SIDA-
dc.subject.decsHIV Antibodies-
dc.subject.decsAnticuerpos Anti-VIH-
dc.description.researchgroupidCOL0012444spa
dc.relation.ispartofjournalabbrevFront. Immunol.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
FlorezLizdany_2018_NKCellsHIV1.pdfArtículo de revisión1.64 MBAdobe PDFVisualizar/Abrir
FlorezLizdany_2018_NKCellsHIV1.epubArtículo de revisión1.67 MBEPUBVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons